Taxanes induced hypersensitivity reactions in cancer chemotherapy patients reported at adverse drug reaction monitoring centre at a tertiary care hospital
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20223350Keywords:
Taxanes, Cancer chemotherapy, Hypersensitivity reactionsAbstract
Background: Cancer chemotherapy involves highly complex regimens using antineoplastic agents like taxanes (paclitaxel, docetaxel) etc. Taxanes cause hypersensitivity reactions (HSRs) like redness, rashes, dyspnoea, severe anaphylaxis and death. In this study, adverse drug reactions (ADRs) associated with taxanes are described & analysed on their severity and preventability. The present study aims to analyse and determine the prevalence of ADRs, especially HSRs in patients treated with taxanes.
Methods: After getting IEC approval, the present study is done retrospectively by assessing the HSRs in suspected ADR reporting forms from December 2019 to February 2022 in ADR monitoring centre (AMC) in the Department of Pharmacology at Kurnool Medical College, Kurnool. Descriptive statistics used to analyse patient demography, frequency, various carcinomas under treatment & organ involved, causality assessment using WHO-UMC Scale and Naranjo's Algorithm, severity assessment using modified Hartwig & Siegel’s scale and preventability by modified Schumock & Thornton scale.
Results: A total of 258 ADRs were recorded, of which 30 cases reported HSRs with taxanes-paclitaxel (22) and docetaxel (8). The most commonly occurred HSR is shortness of breath. Naranjo’s algorithm showed 52.5% possible (score 1-4) HSRs. WHO-UMC causality assessment scale showed 56.4% as probable HSRs. Modified Hartwig & Siegel severity scale showed 46.6% moderate (level 3). Modified Schumock and Thornton scale showed 76.9% as not preventable.
Conclusions: Chemotherapy-related ADRs among cancer patients urges the oncologists to be actively involved in ADR reporting, in the need of the hour in order to mitigate, avoid their occurrence and reducing morbidity and mortality, when practiced with diligence.
Metrics
References
Surendiran A, Balamurugan N, Gunaseelan K, Akhtar S, Reddy K, Adithan C. Adverse drug reaction profile of cisplatin-based chemotherapy regimen in a tertiary care hospital in India: An evaluative study. Indian J Pharmacol. 2010;42(1):40.
Kang R, Yoo K, Han H, Lee J. Evaluation of the effects and adverse drug reactions of low-dose dexamethasone premedication with weekly docetaxel. Support Care Cancer. 2016;25(2):429-37.
Chopra D, Rehan HS, Sharma V, Mishra R. Chemotherapy-induced adverse drug reactions in oncology patients: A prospective observational survey. Indian J Med Paediatr Oncol. 2016;37:42-6.
Lal L, Gerber D, Lau J, Dana W. Retrospective evaluation of weekly paclitaxel hypersensitivity reactions reported utilizing an electronic medical record system at a tertiary cancer center. Supportive Care Cancer. 2009;17(10):1311-5.
Gupta V, Shivaprakash G, Bhattacherjee D, Udupa K, Poojar B, Sori R et al. Association of health literacy and cognition levels with severity of adverse drug reactions in cancer patients: a South Asian experience. Int J Clin Pharm. 2020;42(4):1168-74.
Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available at: http://ctep.cancer.gov. Accessed on 20 November 2022.
Niggemann B, Beyer K. Time for a new grading system for allergic reactions? Allergy. 2015;71(2):135-6.
Farrar MC, Jacobs TF. Paclitaxel. Treasure Island (FL): StatPearls Publishing; 2022.
Kloover J, Bakker M, Gelderblom H, Meerbeeck J. Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. Br J Cancer. 2004;90(2):304-5.
Wahlang J, Laishram P, Brahma D, Sarkar C, Lahon J, Nongkynrih B. Adverse drug reactions due to cancer chemotherapy in a tertiary care teaching hospital. Therap Adv Drug Safety. 2016;8(2):61-6.
Downloads
Published
How to Cite
Issue
Section
